OncoZenge AB (FRA:8LY) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Other Long-Term Liabilities?

OncoZenge AB's other long-term liabilities for the quarter that ended in Sep. 2024 was €0.00 Mil.

OncoZenge AB Other Long-Term Liabilities Historical Data

The historical data trend for OncoZenge AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Other Long-Term Liabilities Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long-Term Liabilities	Get a 7-Day Free Trial											-	-	-	-	-

OncoZenge AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

OncoZenge AB Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ONCOZ:Sweden

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines